SRPT (STOCKS)
Sarepta Therapeutics,, Inc. Common Stock
$21.920000
+0.740000 (+3.49%)
Prev close: $21.180000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Douglas S. Ingram
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $2,285.11M
- Employees
- 1,372
- P/E (TTM)
- -2.58
- P/B (TTM)
- 2.01
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
7
Strong Buy
6
Buy
15
Hold
4
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$-3.93 | $-1.26 | -2.6746 | -213.05% |
|
Sep 2025 (Q3)
|
$-0.01 | $-0.83 | +0.8217 | +98.80% |
|
Jun 2025 (Q2)
|
$1.89 | $0.77 | +1.1243 | +146.83% |
|
Mar 2025 (Q1)
|
$-4.60 | $-0.97 | -3.6341 | -376.24% |
Financial Statements
| Revenues | $2.20B |
| Benefits Costs and Expenses | $2.90B |
| Cost Of Revenue | $25.50M |
| Costs And Expenses | $2.90B |
| Gross Profit | $2.17B |
| Nonoperating Income/Loss | -$2.44M |
| Operating Expenses | $2.87B |
| Selling, General, and Administrative Expenses | $491.72M |
| Other Operating Expenses | $2.38B |
| Operating Income/Loss | -$699.78M |
| Income/Loss From Continuing Operations After Tax | -$713.41M |
| Income/Loss From Continuing Operations Before Tax | -$702.23M |
| Income/Loss From Equity Method Investments | $0.00 |
| Income Tax Expense/Benefit | $11.19M |
| Income Tax Expense/Benefit, Current | $11.55M |
| Income Tax Expense/Benefit, Deferred | -$363.00K |
| Interest Expense, Operating | -$38.14M |
| Net Income/Loss | -$713.41M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$713.41M |
| Net Income/Loss Available To Common Stockholders, Basic | -$713.41M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$7.13 |
| Diluted Earnings Per Share | -$7.13 |
| Basic Average Shares | 100,120,000 |
| Diluted Average Shares | 100,120,000 |
| Assets | $3.35B |
| Current Assets | $2.54B |
| Inventory | $914.74M |
| Other Current Assets | $1.62B |
| Noncurrent Assets | $811.77M |
| Fixed Assets | $345.13M |
| Other Non-current Assets | $466.64M |
| Liabilities | $2.21B |
| Current Liabilities | $1.10B |
| Accounts Payable | $280.84M |
| Wages | $58.61M |
| Other Current Liabilities | $755.84M |
| Noncurrent Liabilities | $1.11B |
| Long-term Debt | $828.97M |
| Other Non-current Liabilities | $284.82M |
| Equity | $1.14B |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $1.14B |
| Liabilities And Equity | $3.35B |
| Net Cash Flow From Operating Activities | -$205.48M |
| Net Cash Flow From Operating Activities, Continuing | -$205.48M |
| Net Cash Flow From Investing Activities | $69.64M |
| Net Cash Flow From Investing Activities, Continuing | $69.64M |
| Net Cash Flow From Financing Activities | -$168.34M |
| Net Cash Flow From Financing Activities, Continuing | -$168.34M |
| Net Cash Flow | -$304.18M |
| Net Cash Flow, Continuing | -$304.18M |
| Comprehensive Income/Loss | -$712.92M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$712.92M |
| Other Comprehensive Income/Loss | $490.00K |